-+ 0.00%
-+ 0.00%
-+ 0.00%

Compugen publishes corporate presentation on AI-driven immuno-oncology antibody pipeline

PUBT·08/03/2026 11:12:57
Listen to the news
Compugen publishes corporate presentation on AI-driven immuno-oncology antibody pipeline
  • Compugen highlighted a cash balance of $125.3 million as of June 30, 2026, with expected runway into 2029.
  • COM701 maintenance study in relapsed platinum-sensitive ovarian cancer targets an interim analysis in Q1 2027.
  • AstraZeneca’s rilvegostomig program entered Phase 3, with Compugen eligible for up to $195 million milestones, tiered royalties up to mid-single digit.
  • Gilead-licensed GS-0321 anti-IL-18BP program advanced in Phase 1; deal value up to $848 million with single- to low double-digit royalties.
  • Pipeline focus remains on novel immuno-oncology antibodies discovered via the Unigen AI/ML target discovery platform.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.